+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Growth Opportunities in Global Pharmaceutical Logistics

  • Report

  • 56 Pages
  • December 2022
  • Region: Global
  • Frost & Sullivan
  • ID: 5725724

Cold chain Investments and Hybrid Clinical Trials to Ensure Transformational Growth of Pharmaceutical Logistics

Medicine production supply chains are currently operating under huge stress due to the war in Ukraine, COVID-19-related disruptions, logistics bottlenecks, and inflation. An energy-related shutdown of production would have a detrimental effect on the supply of critical medicines to patients in the EU and worldwide. The excessive amount of pressure on healthcare supply chains worldwide is driving companies to address vulnerabilities. Pharmaceutical companies will need to rely heavily on an unprecedented level of cooperation from raw material suppliers, government agencies, and contract development and manufacturing organizations.

The increasing focus on biologics, adoption of technology, and shift to a patient-centric model are transforming the pharma logistics market; the COVID-19 pandemic has sped up the rate of transformation and acted as a catalyst for the adoption of decentralized trials. This has increased the complexity of coordination of not only clinical trial supply management but also healthcare professionals, and arranging necessary infrastructure for drug storage and infusion.

This research analytics on the global pharmaceutical logistics market identifies some of the leading growth opportunity areas in cold chain capabilities for next-generation vaccines and biologics and hybrid trial logistics ensuring patient enrollment and diversity, highlighting the improved last-mile connectivity to propagate the anytime-anywhere care business model. In addition, the market is witnessing the simultaneous adoption of predictive supply chain solutions that optimize pharma operations and improve profitability.

Table of Contents

1. Strategic Imperatives
  • Why is it Increasingly Difficult to Grow?
  • The Strategic Imperative 8™
  • The Impact of the Top 3 Strategic Imperatives on the Pharmaceutical Logistics Industry
  • Growth Opportunities Fuel the Growth Pipeline Engine™
2. Growth Opportunity Analysis
  • Scope of Analysis
  • Segmentation
  • Market Dynamics
  • Value Chain Analysis
  • Key Competitors
  • Vendor Landscape
  • Growth Drivers for Pharmaceutical Logistics
  • Growth Restraints for Pharmaceutical Logistics
  • Regional Analysis - North America (NA)
  • Regional Analysis - Europe
  • Regional Analysis - United Kingdom (UK)
  • Regional Analysis - Asia-Pacific (APAC)
  • Contract-logistics-provider-related Developments
  • Supply-chain-solution-provider-related Developments
  • CDMO-r
  • CRO-related Developments
  • Pharma LogisticsPrimed for Business Model Disruption
3. Growth Opportunity Universe
  • Growth Opportunity Universe - A Summary
  • Growth Opportunity Universe Summary
  • Growth Opportunity 1: Repurposing Cold Chain Capabilities
  • Global Cold-Chain Products Sales
  • Global Cold-Chain Logistics Spending
  • Global Cold-Chain Logistics Spending
  • Growth Opportunity 2: Hybrid Trial Logistics
  • Case Study - DHL
  • Case Study - Marken (UPS)
  • Growth Opportunity 3: Improved Last-mile Connectivity
  • eCommerce - Disrupting the Traditional Supply Chain Model
  • Case Study - Capsule
  • Growth Opportunity 4: Predictive Supply Chain
  • Case Study - Trek Therapeutics Uses Ambrosus’ Blockchain Solution for Quality Control
  • Case Study - Macro-Eyes’ ML Solutions Bring Predictability to the Vaccine Supply Chain
  • Companies to Action
  • List of Exhibits
  • Legal Disclaimer

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Capsule
  • DHL
  • Marken (UPS)